IMU

2.08%

4.9¢ imugene limited

Ann: Change of Director's Interest Notice - PH, page-165

First 165 Last

Share
Profile

Follow
DTshares

1,074 Posts.

452

24/04/24

14:42

Post #: 73499256
Share

Originally posted by Steini: ↑

If that " How could she / he ...." causes the sub 7c gaps to be filled I would thank the Hoppers for selling. If anyone needs a reason to sell IMU shares then that is the one. Worse than any trial data disappointments, missed time lines or failed asset sales.

But all these posts seem to indicate that there is nothing else atm about IMU to comment on.

Big question, how low will the sp go due to this "outrageous" behaviour of the Hopper family?

GLTA

Expand

Originally posted by HamishM: ↑

Steini my son, when the company needs to undertake another CR, if it is done in a similar fashion to the last 2 CRs, a poor prevailing share price will mean the funds raised will be very, very expensive money for the enterprise that we own. That is because as the shares are issued at a very low price, we the current owners are savagely diluted in our equity in the enterprise. Why is this topical? Because Hopper's actions around his own very, very privileged ownership of shares in IMU so often contribute to the market's diminished view of the prospects of the company. But I am certain you know all this!!?? I am pretty sure you also understand that the company's cash burn is now clicking along at a fast rate due to the number of trials underway! If per chance, you have better maths than I do, I think many of us would benefit from an alternative explanation....
PS Do you have any insight into when Leslie and Paul will release the next 4C?
My opinions only. DYOR

Expand

one thing I just noticed by coincidence is that paa (biotech, not held) managed to raise at a PREMIUM last year (dec).

Why could IMU not do that?

Perhaps dilution was useful after all?

Originally posted by hargeo: ↑

Dingo,
I heard her say that, it was along the lines of “monetising some of our assets”, which she stated within the last couple of weeks. I reckon in hindsight she was referring to the “UP TO $6m in upfront and milestone payments to Imugene from the recent deal with Kincell. A very misleading use of words if that’s the case, as it’s chicken feed in the scheme of things, and a frustratingly ambiguous description anyway, ie how much upfront, how much milestone and how flexible is the “up to”…??
For the record, Imugene paid USD, $8m cash, $13m deferred until Aug 24, and $3m to Chimeric in August last year for the Azercel deal, which included the manufacturing facility.
My main question here is if the Kincell deal relieves Imugene of $32m in staff cost reductions over 3 years, was there no revenue? If it is a net saving of $32m to run the place, what on earth made them think it was affordable to take on this overhead for a non revenue business as recently as August last year???
So many of Hoppers decisions are poor, and seemingly not in the direct interest of shareholders.

Expand

IMU Price at posting: 8.3¢ Sentiment: None Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 61 more messages in this thread...

First 165 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 4.9¢		Change 0.001(2.08%)		Mkt cap ! $364.4M

Open	High	Low	Value	Volume
4.8¢	5.0¢	4.8¢	$458.6K	9.378M

Buyers (Bids)

No.	Vol.	Price($)
6	1039220	4.9¢

Sellers (Offers)

Price($)	Vol.	No.
5.0¢	5436876	20

View Market Depth

No.	Vol.	Price($)
6	1039220	0.049
57	7914687	0.048
41	4254383	0.047
44	3092200	0.046
59	6040180	0.045

Price($)	Vol.	No.
0.050	5436876	20
0.051	5720139	13
0.052	2536519	9
0.053	1539304	8
0.054	1596999	6

Last trade - 16.10pm 07/10/2024 (20 minute delay)

IMU (ASX) Chart

Ann: Change of Director's Interest Notice - PH, page-165

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Change of Director's Interest Notice - PH, page-165

Top Stories

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News